Rizzo, Alan Villarreal

Abstract Background Recent studies suggested that treating obesity and its comorbidities with glucagon-like peptide-1 (GLP-1) receptor agonists may improve outcomes in patients with heart failure with preserved ejection fraction (HFpEF). The randomized SUMMIT trial found that tirzepatide use was associated with a lower risk of heart failure (HF) events or cardiovascular death in adults with HFpEF and obesity compared with placebo. Purpose We aimed to examine whether tirzepatide use in clinical practice was associated with risks of HF events and all-cause mortality among adults with HFpEF and obesity. Methods This was a retrospective cohort study leveraging the Optum Labs Data Warehouse (OLDW), a de-identified administrative claims database of commercial and Medicare Advantage enrollees across the United States. We identified all adults with HFpEF and obesity from January 1, 2022, to December 31, 2024. Our primary exposure was tirzepatide use, and our primary outcome was a composite of a HF event (ED visits or hospitalization for HF) or mortality. Secondary outcomes included hospitalization for angina, atrial fibrillation or atrial flutter (AF/AFL), acute myocardial infarction (MI), cardiac arrest, and cardiogenic shock. Patients were followed from the index date, defined as the tirzepatide treatment start date after HFpEF diagnosis or pseudo-index date in tirzepatide non-users, to the end of enrollment or death using the intention-to-treat framework. Inverse probability of treatment weighting (IPTW) was used to balance groups. Fracture, conjunctivitis, ear infection, and fungal skin infection were used as falsification endpoints. Cox-proportional and Fine-Gray subdistribution hazard models were used to estimate a hazard ratio (HR) and subdistribution hazard ratio (SHR), respectively. Results Among our total cohort of 99,270 patients, the mean age was 73 years, 58,616 (59.1%) were female, 8,839 (8.9%) used tirzepatide, and the mean follow-up time was about 385 days. Patients using tirzepatide had a significantly lower risk of a HF event or mortality (HR=0.73; 95% confidence interval [CI]=0.66–0.80; p<0.001) compared to patients not using tirzepatide. Patients using tirzepatide had a lower risk of a HF event (SHR=0.80; 95% CI=0.73–0.88; p<0.001) and all-cause mortality (HR=0.48; 95% CI=0.38–0.60; p<0.001). Tirzepatide use was associated with lower risks of hospitalization for acute MI (SHR=0.67; 95% CI=0.52–0.85; p=0.001) and cardiogenic shock (SHR=0.56; 95% CI=0.38–0.83; p=0.003), but not angina, AF/AFL, or cardiac arrest (Figure 1). Conclusion Among adults with HFpEF and obesity, tirzepatide use in real-world clinical practice was associated with a lower risk of HF events, hospitalizations for acute cardiovascular disease, and all-cause mortality.For image description, please refer to the figure legend and surrounding text.

Objective To examine sex differences in the relationship between comorbid anemia and heart failure (HF) with 13-year all-cause mortality in Mexican American older adults aged 75 years and older. Methods Participants ( N = 1,615) aged ≥75 years were from the Hispanic Established Population for the Epidemiologic Study of the Elderly (2004/05–2016). Participants were categorized by anemia status, HF status, and sex. Cox proportional hazards regression models estimated hazard ratios (HRs) and 95% Confidence Intervals (CIs) for all-cause mortality. Results HF only was associated with higher mortality in males (HR = 1.41, 95% CI = 1.12–1.78; p = 0.0039) and females (HR = 1.52, 95% CI = 1.24–1.85; p < 0.0001). Anemia only (HR = 1.54, 95% CI = 1.06–2.23; p = 0.0248) and comorbid anemia and HF (HR = 1.74; 95% CI = 1.00–3.03; p = 0.0484) were associated with higher mortality only in males. Conclusion Anemia and HF were associated with greater mortality risk among older Mexican American males than females.

Abstract Background Normal weight obesity (NWO) has been linked to metabolic syndrome (MetS), cardiovascular disease (CVD) and mortality, but has not been comprehensively studied in the Hispanic population. Purpose Our study aims to examine the CVD risk factors associated with NWO and to compare the development of CVD risk factors between NWO and normal weight non-obese (NWNO) Hispanic adults over 6 years. Methods This is a prospective study using data from the Hispanic Community Health Study (HCHS). Interviews and clinical assessments were collected from 2008–2011 (visit 1) to 2014–2017 (visit 2). NWO was defined as a body mass index (BMI) between 18.5–24.9 kg/m2 and a body fat percentage of ≥25 % in men and ≥35% in women, estimated using the Tanita scale. We identified 1,000 HCHS participants as having a normal weight at visit 1 and not missing data on covariates of interest including hypertension (HTN), hyperlipidemia (HLD), MetS, and insulin resistance (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≥2.5). Participants were categorized into NWO (n=104) or NWNO (n=896) groups. Univariate logistic regression models were used to estimate the odds ratio (OR) and 95% confidence intervals (CI) of the association between health risk factors and NWO. Multivariate logistic regression models were used to estimate the odds of developing CVD risk factors over 6 years, using propensity score matching. Results The prevalence of NWO among our sample of Hispanic adults was 10.4% and the 6-year incidence of NWO at visit 2 was 3.5% (n=31) from NWNO participants at visit 1. Higher BMI (OR=5.19; 95% CI=3.15–9.27, p&lt;0.001) and a higher mean overnight heart rate (OR=1.34; 95% CI=1.01–1.79, p=0.043) were statistically significantly associated with NWO at visit 1. Furthermore, HTN (OR=2.88; 95% CI=1.31–6.71, p=0.011), HLD (OR=2.12; 95% CI=1.21–3.77, p=0.009), and MetS (OR=3.48; 95% CI=1.62–8.09, p=0.002) were statistically significantly associated with NWO at visit 1. Participants with NWO at visit 1 had higher odds of developing insulin resistance (OR=1.79; 95% CI=1.07–3.04, p=0.029) and MetS (OR=2.03; 95% CI=1.15–3.66, p=0.016) at visit 2 compared to NWNO participants at visit 1, after age and sex matching. Conclusion Among Hispanic adults, the prevalence of NWO was associated with a higher BMI, higher mean overnight heart rate, treated HTN, HLD, and MetS. Hispanic adults with NWO were more likely to develop insulin resistance and MetS over 6 years compared to NWNO Hispanic adults. Overall, NWO among Hispanic adults was associated with CVD risk factors which places this population at a higher risk for CVD morbidity and mortality.

Resistant hypertension (RH) is a high-risk phenotype characterized by blood pressure readings ≥130/80 mmHg despite maximally tolerated therapy with three antihypertensive agents, including a diuretic, or controlled blood pressure requiring four or more medications. The diagnosis of RH requires a structured evaluation that confirms accurate blood pressure measurement, excludes pseudoresistance—particularly nonadherence and white coat hypertension—and identifies secondary causes such as obstructive sleep apnea, primary aldosteronism, renovascular disease, pheochromocytoma, and Cushing syndrome. RH arises from overlapping mechanisms, including activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic overactivity, arterial stiffness, volume expansion, and immune-mediated pathways. Management begins with lifestyle modification and optimized triple therapy, followed by mineralocorticoid receptor antagonists as the preferred fourth-line treatment. Emerging pharmacological options, such as sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin receptor antagonists, aldosterone synthase inhibitors, and angiotensin receptor and neprilysin inhibitors (ARNIs), offer additional therapeutic potential; meanwhile, device-based interventions, including renal denervation and baroreflex activation therapy, have shown sustained blood pressure reductions in selected patients. Future directions highlight precision medicine, digital health technologies, and artificial intelligence as methods to improve diagnosis, guide individualized therapy, and enhance long-term blood pressure control.

Objectives Few studies have investigated health outcomes associated with arthritis in low-middle-income countries. Our objective was to examine the association between arthritis and all-cause hospitalization and mortality among middle-aged and older adults in Mexico. Methods Our sample included 12,106 participants aged >50 years from the 2012, 2015, and 2018 waves of the Mexican Health and Aging Study. Logistic regression was used for the associations between arthritis and hospitalization. Kaplan–Meier and Cox proportional hazard models were used for the association between arthritis and mortality. Results Arthritis was associated with higher odds of hospitalization (OR = 1.23; 95% CI = 1.09–1.38), but not mortality. Arthritis with physical limitations had the highest odds of hospitalization (OR = 1.48; 95% CI = 1.27–1.73). Arthritis with joint pain (OR = 1.24; 95% CI = 1.10–1.41) and medication use (OR = 1.28; 95% CI = 1.11–1.48) had higher odds of hospitalization. Conclusion Among middle-aged and older adults in Mexico, arthritis was associated with a high risk of hospitalization.

Background: Radial artery (RA) access has become common in cardiac catheterization due to fewer vascular complications and MACE compared to transfemoral approach (TFA). However, anatomic variations are more profound in the upper-extremity. Research Question: What are common anatomic variations encountered during transradial approach (TRA) coronary angiography and what association do they have with adverse outcomes and procedural challenges? Methods: We performed a single-center retrospective analysis of 926 patients who underwent coronary angiography through TRA via the right upper-extremity where RA angiogram was performed from 01/2010 to 01/2023. Multivariate logistic regression was utilized to estimate the odds ratio (OR) of the association between anatomic variations and adverse outcomes and procedural challenges. Results: A total of 926 patients with a mean age of 59.9 years were studied with 30.4% being female. Common comorbidities were HTN (82.2%), HLD (51.8%), and DM (45%). About 32% of patients had an anatomic variation. Prevalences were 14.4% radial tortuosity, 12% high RA bifurcation, 11.9% M-sign, and 1% RA loops. These patients were older (P<0.001) and more likely to have HLD (P=0.049). They had high odds of high contrast dose (OR 1.73; 95% CI 1.28-2.34, P<0.001), long fluoroscopy time (OR 2.02; 95% CI 1.50-2.73, P<0.001), high radiation exposure (OR 2.47; 95% CI 1.79-3.42, P<0.001), difficulty engaging coronary arteries (OR 2.70; 95% CI 1.94-3.74, P<0.001), and transfer to TFA (OR 4.89; 95% CI 2.36-10.12, P<0.001). Females (OR 2.89; 95% CI 2.01-4.15, P<0.001), small RA size (OR 2.61; 95% CI 1.76-3.86, P<0.001), high RA bifurcation (OR 1.68; 95% CI 1.02-2.75, P=0.04), and M-sign (OR 2.04; 95% CI 1.24-3.35, P=0.005) were associated with RA spasm. Major complications were not significant. Conclusion: We found a high prevalence of anatomic variations. They were associated with high odds of adverse outcomes and procedural challenges during TRA coronary angiography.